The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Developments in the management of all stages of prostate cancer are taking place on a regular basis. New biomarkers and evolving insight into genetic testing are giving guidance in prostate cancer decision making including treatment choices. PET scans have not been widely applied to prostate cancer, but newer agents are making this a more useful imaging approach. Biomarkers, genetics, PET imaging and new medications are the focus of this talk.
Continuing Education Instructions and Disclosure Information:
Contact hours available until 4/18/23.
Requirements for Successful Completion: Complete the learning activity in its entirety and complete the online nursing continuing professional development evaluation. You will be able to print your NCPD certificate at any time after you complete the evaluation.
Faculty, Planners, and Speakers Conflict of Interest Disclosure:
Planning Committee Disclosures: Julie A. Starr, PhD, APRN – Consultant for The Prometheus Group
There are no other Planning Committee disclosures to declare.
Speakers Conflict of Interest Disclosure: There are no speaker disclosures to declare.
Commercial Support and Sponsorship: No commercial support or sponsorship declared.
Accreditation Statement: The Society of Urologic Nurses and Associates (SUNA) is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
SUNA accreditation is reciprocal in the states and specialty organizations that recognize the ANCC-COA accreditation process. SUNA is also an approved provider of continuing nursing education by the California Board of Registered Nursing, Provider Number CEP 5556. Accreditation and approved provider status of NCPD does not imply ANCC-COA approval or endorsement of any product, advertising, or educational content. SUNA urges all participants to be aware of the CE requirements for re-licensure in the states in which they hold a license.
Learning Outcome: After completing this education activity, the learner will be knowledgeable about new diagnostics and treatment modalities for advanced prostate cancer.
Speaker(s):
Leonard
Gomella,
MD, FACS,
Professor and Chair of Urology,
Thomas Jefferson University Hospital
You must be logged in and own this session in order to
post comments.
Karina So
9/3/22 2:16 am
Great slide set! Thank you for a learning opportunity.
Jennfier Knoke
9/16/22 1:53 pm
Thank you for this information. I would like to hear more regarding the Chek2 gene mutation and follow up recommendations, specifically is somatic genetic testing recommended. I had a father that was positive for prostate cancer at age 60, brother age 44 with prostate cancer. I had for many years been asking if there was a line with breast cancer and for a long time the answer was no. I was diagnosed with Breast cancer in 2020 and found positive for Chek2 mutation and learned this link between the two cancers. I have worked in Urology for many years and had been asking regarding link between this and breast cancer and am glad the link has been made finally. More information would be so helpful.
Karina So
9/3/22 2:16 am
Great slide set! Thank you for a learning opportunity.